All In Biotech

Drug Trial Radar · NCT05394103

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Aug 30, 2022

Primary completion

Mar 31, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Qurient Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Conditions

  • Advanced Cancer
  • Metastatic Cancer

Interventions

  • Mocaciclib (Q901)Drug

    The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter

  • KEYTRUDA® (pembrolizumab)Drug

    KEYTRUDA® (pembrolizumab) will be administered Q6W

  • FulvestrantDrug

    Fulvestrant will be administered as per the drug label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 28 days of cycle 1 (each cycle is 28 days)

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Atlantic Health System Hospital

    Morristown, New Jersey · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • Keimyung University

    Daegu, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

  • CHA University Bundang Medical Center

    Seongnam-si, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Ajou University

    Suwon, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.